EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

[1]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[2]  A. Lok,et al.  Hepatitis B cure: From discovery to regulatory approval. , 2017, Journal of hepatology.

[3]  M. Yuen,et al.  Hepatitis B virus core‐related antigen as a surrogate marker for covalently closed circular DNA , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[4]  M. Manns,et al.  EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. , 2017, Journal of hepatology.

[5]  M. Buti,et al.  Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study , 2017 .

[6]  P. Marcellin,et al.  Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open- , 2017, The lancet. Gastroenterology & hepatology.

[7]  Lai Wei,et al.  Serum HBV core‐related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients , 2017, Journal of medical virology.

[8]  Vincent Wai-Sun Wong,et al.  The role of quantitative hepatitis B surface antigen revisited. , 2017, Journal of hepatology.

[9]  M. Manns,et al.  Antiviral treatment and liver‐related complications in hepatitis delta , 2017, Hepatology.

[10]  J. Niu,et al.  Reply to: "Serum HBV pgRNA as a clinical marker for cccDNA activity": Consistent loss of serum HBV RNA might predict the "para-functional cure" of chronic hepatitis B. , 2017, Journal of hepatology.

[11]  T. Volz,et al.  Serum HBV pgRNA as a clinical marker for cccDNA activity. , 2017, Journal of hepatology.

[12]  M. Yuen,et al.  Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. , 2017, Journal of hepatology.

[13]  J. Gallant,et al.  A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults , 2017, Journal of acquired immune deficiency syndromes.

[14]  F. Heinemann,et al.  Humoral and Cellular Responses to a Single Dose of Fendrix in Renal Transplant Recipients with Non‐response to Previous Hepatitis B Vaccination , 2017, Scandinavian journal of immunology.

[15]  F. Cao,et al.  Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus , 2016, Journal of gastroenterology and hepatology.

[16]  M. Buti,et al.  A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96 , 2017 .

[17]  A. Gaggar,et al.  Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks , 2017 .

[18]  T. Berg,et al.  Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. , 2017, Journal of hepatology.

[19]  H. Ding,et al.  The efficacy and safety comparison between tenofovir and entecavir in treatment of chronic hepatitis B and HBV related cirrhosis: A systematic review and Meta‐analysis , 2017, International immunopharmacology.

[20]  R. Mikolajczyk,et al.  Time trends of chronic HBV infection over prior decades - A global analysis. , 2017, Journal of hepatology.

[21]  J. Chen,et al.  Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct‐acting Antiviral Agents , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[22]  J. Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2016. , 2017, Journal of hepatology.

[23]  Yu-Hua Li,et al.  Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis , 2017, Clinical and Experimental Medicine.

[24]  T. Tseng,et al.  Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[25]  G. Gerken,et al.  Treatment of fulminant acute Hepatitis B with nucles(t)id analogues is safe and does not lead to secondary chronification of Hepatitis B , 2016, Zeitschrift für Gastroenterologie.

[26]  O. Mir,et al.  Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  T. Asselah,et al.  Baseline HBsAg and HBcrAg titres allow peginterferon‐based ‘precision medicine’ in HBeAg‐negative chronic hepatitis B patients , 2016, Journal of viral hepatitis.

[28]  M. Buti,et al.  Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B , 2016, Alimentary pharmacology & therapeutics.

[29]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[30]  M. Buti,et al.  Flares during long‐term entecavir therapy in chronic hepatitis B , 2016, Journal of gastroenterology and hepatology.

[31]  Yan Zhou,et al.  HBV DNA Integration and Clonal Hepatocyte Expansion in Chronic Hepatitis B Patients Considered Immune Tolerant. , 2016, Gastroenterology.

[32]  J. Kao,et al.  No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  W. Chie,et al.  Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection , 2016, Hepatology.

[34]  Domenico Di Carlo,et al.  Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[35]  J. Gallant,et al.  Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults , 2016, Journal of Acquired Immune Deficiency Syndromes.

[36]  N. Xia,et al.  Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. , 2016, Journal of hepatology.

[37]  C. Delaugerre,et al.  Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. , 2016, Journal of hepatology.

[38]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[39]  W. Qu,et al.  Entecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: a meta-analysis , 2016, Scientific Reports.

[40]  J. Stapleton,et al.  Hepatitis Viruses in Kidney Transplantation. , 2016, Seminars in nephrology.

[41]  G. Papatheodoridis,et al.  The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy , 2016, Clinical and molecular hepatology.

[42]  W. Haefeli,et al.  First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. , 2016, Journal of hepatology.

[43]  G. Fattovich,et al.  Incidence of hepatocellular carcinoma in untreated subjects with chronic hepatitis B: a systematic review and meta‐analysis , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[44]  Thorsten Lehr,et al.  Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. , 2016, Journal of hepatology.

[45]  P. Lampertico,et al.  Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection , 2016, Alimentary pharmacology & therapeutics.

[46]  S. Chevret,et al.  First international external quality assessment for hepatitis delta virus RNA quantification in plasma , 2016, Hepatology.

[47]  S. Bae,et al.  Entecavir plus tenofovir combination therapy in patients with multidrug‐resistant chronic hepatitis B: results of a multicentre, prospective study , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[48]  T. Berg,et al.  Review article: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients , 2016, Alimentary pharmacology & therapeutics.

[49]  H. Toyoda,et al.  HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. , 2016, Journal of hepatology.

[50]  A. Andriulli,et al.  HBsAg kinetics in chronic hepatitis D during interferon therapy: on‐treatment prediction of response , 2016, Alimentary pharmacology & therapeutics.

[51]  L. Dal Maso,et al.  Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[52]  Shuqin Zhang,et al.  Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. , 2016, The New England journal of medicine.

[53]  M. Bazinet,et al.  Safety and Efficacy of Nucleic Acid Polymers in Monotherapy and Combined with Immunotherapy in Treatment-Naive Bangladeshi Patients with HBeAg+ Chronic Hepatitis B Infection , 2016, PloS one.

[54]  G. Ruoppolo,et al.  Polyarteritis nodosa: A contemporary overview. , 2016, Autoimmunity reviews.

[55]  V. Pattullo.  Prevention of Hepatitis B reactivation in the setting of immunosuppression , 2016, Clinical and molecular hepatology.

[56]  N. Chuaypen,et al.  Serum hepatitis B core‐related antigen as a treatment predictor of pegylated interferon in patients with HBeAg‐positive chronic hepatitis B , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[57]  Hongbing Shen,et al.  Genome-wide association study identifies 8p21.3 associated with persistent hepatitis B virus infection among Chinese , 2022 .

[58]  B. Kearney,et al.  Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment , 2016, Antimicrobial Agents and Chemotherapy.

[59]  K. Simon,et al.  Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure , 2016, Hepatology International.

[60]  J. V. van Steenbergen,et al.  Fluctuation of Viremia in Hepatitis B Virus–Infected Healthcare Workers Performing Exposure-Prone Procedures in the Netherlands , 2016, Infection Control & Hospital Epidemiology.

[61]  P. Lampertico,et al.  Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders , 2016, Expert opinion on biological therapy.

[62]  E. Cholongitas,et al.  Discontinuation of oral antivirals in chronic hepatitis B: A systematic review , 2016, Hepatology.

[63]  R. Anty,et al.  Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge. , 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[64]  A. J. van der Meer,et al.  Posttreatment Hepatitis B Surface Antigen Seroreversion: The Bane of Combination Therapy in Chronic Hepatitis B? , 2016, Gastroenterology.

[65]  T. Berg,et al.  Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). , 2016, The Lancet. Infectious diseases.

[66]  R. Schmidt,et al.  Aktuelle Seroprävalenz, Impfstatus und prädiktiver Wert der Leberenzyme für Hepatitis B bei Flüchtlingen in Deutschland , 2016, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[67]  F. Zoulim,et al.  New antiviral targets for innovative treatment concepts for hepatitis B virus and hepatitis delta virus. , 2016, Journal of hepatology.

[68]  M. Buti,et al.  PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. , 2016, Journal of hepatology.

[69]  M. Maini,et al.  The role of innate immunity in the immunopathology and treatment of HBV infection. , 2016, Journal of hepatology.

[70]  S. Zeuzem,et al.  Pre- and Post-Transplant Antiviral Therapy (HBV, HCV) , 2016, Visceral Medicine.

[71]  J. Zucman‐Rossi,et al.  Mechanisms of HBV-induced hepatocellular carcinoma. , 2016, Journal of hepatology.

[72]  D. J. Kim,et al.  An Observational, Multicenter, Cohort Study Evaluating the Antiviral Efficacy and Safety in Korean Patients With Chronic Hepatitis B Receiving Pegylated Interferon-alpha 2a (Pegasys) , 2016, Medicine.

[73]  A. Streinu-Cercel,et al.  Treatment with lamivudine and entecavir in severe acute hepatitis B , 2016, Indian journal of medical microbiology.

[74]  P. Revill,et al.  Overview of hepatitis B viral replication and genetic variability. , 2016, Journal of hepatology.

[75]  A. Bertoletti,et al.  Adaptive immunity in HBV infection. , 2016, Journal of hepatology.

[76]  M. Honda,et al.  Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. , 2016, The Journal of infectious diseases.

[77]  M. Nguyen,et al.  Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy , 2016, Journal of clinical gastroenterology.

[78]  U. Protzer,et al.  Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. , 2016, Journal of hepatology.

[79]  C. Yeh,et al.  Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. , 2016, The Journal of infectious diseases.

[80]  K. Lichtenstein,et al.  Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study , 2016, Journal of acquired immune deficiency syndromes.

[81]  F. Sun,et al.  Systematic review with meta‐analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B , 2016, Alimentary pharmacology & therapeutics.

[82]  Giacomo Germani,et al.  EASL Clinical Practice Guidelines: Liver transplantation , 2016 .

[83]  Q. Wang,et al.  The Lumipulse G HBsAg-Quant assay for screening and quantification of the hepatitis B surface antigen. , 2016, Journal of virological methods.

[84]  P. Rosenthal,et al.  Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen–positive chronic hepatitis B , 2016, Hepatology.

[85]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[86]  Fares Alahdab,et al.  Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta‐analysis , 2016, Hepatology.

[87]  A. Lok,et al.  Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the US – the ENUMERATE study , 2016, Alimentary pharmacology & therapeutics.

[88]  B. McMahon,et al.  Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta‐analysis , 2016, Hepatology.

[89]  C. Mok,et al.  Comparison of efficacy and renal safety of telbivudine and entecavir in treatment-naive elderly patients with chronic hepatitis B , 2015, European journal of gastroenterology & hepatology.

[90]  P. Lampertico,et al.  Add-On Peginterferon Alfa-2a Significantly Reduces HBsAg Levels in HBeAg-Negative, Genotype D Chronic Hepatitis B Patients Fully Suppressed on Nucleot(s)ide Analogues Treatment: Final Results of the Hermes Study , 2016 .

[91]  Mayda Martínez Rodríguez,et al.  Prevents HBV Reactivation with Tenofovir in Anti-HBC Positive Patients with Hematologic Malignancies Treated with Rituximab. Results Final Visit 18-Months (Preblin Study) , 2016 .

[92]  T. Asselah,et al.  Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study , 2016 .

[93]  T. Asselah,et al.  A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B , 2016 .

[94]  F. Zoulim,et al.  Decay of Ccc-Dna is Slow and Marks Persistence of Intrahepatic Viral Dna Synthesis during Long-Term Tenofovir Treatment in Hiv-Hbv Co-Infected Patients , 2016 .

[95]  Yunxin Chen,et al.  Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy. , 2016, Clinical lymphoma, myeloma & leukemia.

[96]  R. Schmidt,et al.  [Current seroprevalence, vaccination and predictive value of liver enzymes for hepatitis B among refugees in Germany]. , 2016, Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz.

[97]  A. Burroughs,et al.  EASL Clinical Practice Guidelines: Liver transplantation. , 2016, Journal of hepatology.

[98]  M. Buti,et al.  Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. , 2016, Gastroenterology.

[99]  J. van Lunzen,et al.  Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. , 2016, The Lancet. Infectious diseases.

[100]  C. Trautwein,et al.  Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany , 2016, Digestive Diseases and Sciences.

[101]  M. Yuen,et al.  Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability , 2016, Journal of Gastroenterology.

[102]  P. Marcellin,et al.  Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France , 2016, Digestive Diseases and Sciences.

[103]  P. Messa,et al.  Novel Perspectives on the Hepatitis B Virus Vaccine in the Chronic Kidney Disease Population , 2015, The International journal of artificial organs.

[104]  M. Manns,et al.  Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[105]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[106]  P. Lampertico,et al.  Optimal management of hepatitis B virus infection - EASL Special Conference. , 2015, Journal of hepatology.

[107]  G. Casazza,et al.  The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. , 2015, Journal of hepatology.

[108]  Gérard Krause,et al.  Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013 , 2015, The Lancet.

[109]  T. Therneau,et al.  Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B , 2015, Cancer.

[110]  J. Feld,et al.  Hepatitis B reactivation in HBsAg‐negative/HBcAb‐positive patients receiving rituximab for lymphoma: a meta‐analysis , 2015, Journal of viral hepatitis.

[111]  F. Cambra,et al.  Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients , 2015, Transplant infectious disease : an official journal of the Transplantation Society.

[112]  Laetitia Canini,et al.  Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. , 2015, The Lancet. Infectious diseases.

[113]  E. Sagnelli,et al.  Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in undocumented migrants and refugees in southern Italy, January 2012 to June 2013. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[114]  徹郎 竹原,et al.  ペグインターフェロン，リバビリン，シメプレビル3剤併用療法にてC型肝炎ウイルスに対して著効が得られるも，HBV DNA量の増加を来したB型C型重複感染の1例 , 2015 .

[115]  R. Klevens,et al.  Epidemiology of Acute Hepatitis B in the United States From Population-Based Surveillance, 2006-2011. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[116]  Mei-Hwei Chang,et al.  Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus , 2015, Hepatology.

[117]  Ding‐Shinn Chen,et al.  Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. , 2015, Journal of hepatology.

[118]  M. Yeh,et al.  Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report , 2015, Journal of Medical Case Reports.

[119]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[120]  F. Anania,et al.  Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[121]  G. Coppolino,et al.  The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists , 2015, Journal of Nephrology.

[122]  M. Nassal.  HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B , 2015, Gut.

[123]  J. Jang,et al.  Long‐term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus–related cirrhosis , 2015, Hepatology.

[124]  H. Wedemeyer,et al.  Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[125]  K. Kitrinos,et al.  Genome‐free hepatitis B virion levels in patient sera as a potential marker to monitor response to antiviral therapy , 2015, Journal of viral hepatitis.

[126]  Wenhong Zhang,et al.  Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment , 2015, Antimicrobial Agents and Chemotherapy.

[127]  G. Bakalos,et al.  On‐treatment prediction of sustained response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B patients , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[128]  C. Seeger,et al.  Molecular biology of hepatitis B virus infection. , 2015, Virology.

[129]  H. Lee,et al.  Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. , 2015, Journal of hepatology.

[130]  K. Simon,et al.  Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) , 2015, Hepatology.

[131]  Deepali Kumar,et al.  Solid Organ Transplantation From Hepatitis B Virus–Positive Donors: Consensus Guidelines for Recipient Management , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[132]  A. Lok,et al.  Preventing hepatitis B reactivation due to immunosuppressive drug treatments. , 2015, JAMA.

[133]  H. Chan,et al.  Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. , 2015, Journal of hepatology.

[134]  Hehan Tang,et al.  O116 : Predictive value of baseline and on-treatment qHBsAg level in HBeAg positive CHB patients who switched from NUCs to pegylated interferon A-2A: A further analysis from new switch study , 2015 .

[135]  S. Bohm,et al.  P0643 : Serum HBV RNA is an early predictor of HBeAg seroconversion in patients with chronic hepatitis B (CHB) treated with Peg-Interferon alpha-2A (40kD) , 2015 .

[136]  M. Buti,et al.  P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC) , 2015 .

[137]  M. Buti,et al.  O117 : Predictors of clinical response: Results from a large, randomized controlled study with tenofovir disoproxil fumarate (TDF) plus peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB) , 2015 .

[138]  L. Baldini,et al.  P0655 : Lamivudine prophylaxis prevents hepatitis B reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non-Hodgkin's B cell lymphoma , 2015 .

[139]  M. Deutsch,et al.  The spectrum of HBV/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management , 2015, Annals of gastroenterology.

[140]  H. Lee,et al.  Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial , 2015, Gut.

[141]  J. Song,et al.  Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir , 2015, Clinical and molecular hepatology.

[142]  Lu Liu,et al.  The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis. , 2015, Annals of hepatology.

[143]  E. Cholongitas,et al.  Management of patients with hepatitis B in special populations. , 2015, World journal of gastroenterology.

[144]  B. Autran,et al.  Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure , 2015, Gut.

[145]  M. Buti,et al.  Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. , 2015, Journal of hepatology.

[146]  A. Lok,et al.  Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune‐suppressing and anticancer drugs: Just the tip of the iceberg? , 2015, Hepatology.

[147]  M. Mcphail,et al.  Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk? , 2015, The Journal of infectious diseases.

[148]  T. Berg,et al.  Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors , 2015, Hepatology.

[149]  T. Santantonio,et al.  Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. , 2014, The Journal of antimicrobial chemotherapy.

[150]  E. Ridruejo.  Antiviral treatment for chronic hepatitis B in renal transplant patients. , 2015, World journal of hepatology.

[151]  Y. Falck‐Ytter,et al.  American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy , 2014 .

[152]  F. Zoulim,et al.  Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. , 2015, Journal of hepatology.

[153]  K. Reddy,et al.  American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. , 2015, Gastroenterology.

[154]  D. Hooper,et al.  In memoriam: Morton N. Swartz. , 2015, The Journal of infectious diseases.

[155]  E. Cholongitas,et al.  The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis , 2015, Annals of gastroenterology.

[156]  M. Buti,et al.  Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection , 2014, Digestive Diseases and Sciences.

[157]  Tongyu Lin,et al.  Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. , 2014, JAMA.

[158]  H. Chan,et al.  A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[159]  Peter Schmid,et al.  Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon‐alpha therapy via mathematical modeling , 2014, Hepatology.

[160]  C. Coffin,et al.  The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long‐term nucleos(t)ide analogue therapy , 2014, Alimentary pharmacology & therapeutics.

[161]  G. Raimondo,et al.  Hepatitis B virus and hepatitis C virus dual infection. , 2014, World journal of gastroenterology.

[162]  A. Goyal,et al.  The Impact of Vaccination and Antiviral Therapy on Hepatitis B and Hepatitis D Epidemiology , 2014, PloS one.

[163]  Xiao-Jun Ma,et al.  Extended peginterferon alfa‐2a (Pegasys) therapy in Chinese patients with HBeAg‐negative chronic hepatitis B , 2014, Journal of medical virology.

[164]  B. McMahon,et al.  Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection. , 2014, Journal of hepatology.

[165]  M. Manns,et al.  Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double‐blinded multicentre trial , 2014, Journal of viral hepatitis.

[166]  Q. Ning,et al.  Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). , 2014, Journal of hepatology.

[167]  H. Nakauchi,et al.  Novel strategies for liver therapy using stem cells , 2014, Gut.

[168]  M. Yuen,et al.  Entecavir treatment in kidney transplant recipients infected with hepatitis B , 2014, Clinical transplantation.

[169]  S. Locarnini,et al.  Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. , 2014, Journal of hepatology.

[170]  Xiaoshun He,et al.  Is Hepatitis B Immunoglobulin Necessary in Prophylaxis of Hepatitis B Recurrence after Liver Transplantation? A Meta-Analysis , 2014, PloS one.

[171]  J. Hwang,et al.  Effect of Virological Response to Entecavir on the Development of Hepatocellular Carcinoma in Hepatitis B Viral Cirrhotic Patients: Comparison Between Compensated and Decompensated Cirrhosis , 2014, The American Journal of Gastroenterology.

[172]  M. Buti,et al.  Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians , 2014, Gut.

[173]  H. Lee,et al.  Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. , 2014, Gastroenterology.

[174]  Jaw-Town Lin,et al.  Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. , 2014, Gastroenterology.

[175]  M. Manns,et al.  Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta , 2014, Hepatology.

[176]  J. Hoofnagle,et al.  Long‐term therapy of chronic delta hepatitis with peginterferon alfa , 2014, Alimentary pharmacology & therapeutics.

[177]  W. Gerlich.  Reduction of Infectivity in Chronic Hepatitis B Virus Carriers among Healthcare Providers and Pregnant Women by Antiviral Therapy , 2014, Intervirology.

[178]  A. Kramvis.  Genotypes and Genetic Variability of Hepatitis B Virus , 2014, Intervirology.

[179]  P. Zhao,et al.  Acute liver failure caused by severe acute hepatitis B: a case series from a multi-center investigation , 2014, Annals of Clinical Microbiology and Antimicrobials.

[180]  I. Hung,et al.  Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment , 2014, Journal of gastroenterology and hepatology.

[181]  H. Chan,et al.  Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. , 2014, Gastroenterology.

[182]  Y. Liaw,et al.  O113 COMBINATION THERAPY WITH PEGINTERFERON ALFA-2a AND A NUCLEOS(T)IDE ANALOGUE FOR HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS: RESULTS OF A LARGE, RANDOMISED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY , 2014 .

[183]  J. J. Moreno,et al.  P1058 LONG-TERM EFFICACY OF TENOFOVIR IN PREVIOUSLY TREATED AND NAIVE PATIENTS. RESULTS FROM THE SPANISH CHRONIC HEPATITIS B REGISTRY (CIBERHEP) , 2014 .

[184]  C. Yurdaydın,et al.  O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY , 2014 .

[185]  R. Idilman,et al.  Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis , 2014 .

[186]  Y. Karino,et al.  Risk factors for long‐term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults , 2014, Hepatology.

[187]  E. Tanaka,et al.  Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[188]  P. Marcellin,et al.  Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. , 2013, Journal of hepatology.

[189]  C. Chu,et al.  Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients , 2013, Hepatology.

[190]  Chien-Jen Chen,et al.  Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma , 2013, Gut.

[191]  S. Rungta,et al.  Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective. , 2013, Antiviral research.

[192]  V. Wong,et al.  Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis , 2013, Hepatology.

[193]  G. Touloumi,et al.  Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. , 2013, Journal of hepatology.

[194]  H. Lee,et al.  HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability , 2013, Gut.

[195]  Q. Su,et al.  Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. , 2013, World journal of gastroenterology.

[196]  G. Mieli-Vergani,et al.  Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. , 2013, Journal of hepatology.

[197]  Y. Liaw,et al.  Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels , 2013, Hepatology.

[198]  Jia-Qi Deng,et al.  Glucocorticoids can increase the survival rate of patients with severe viral hepatitis B: a meta-analysis , 2013, European journal of gastroenterology & hepatology.

[199]  F. Zoulim,et al.  Kinetics of intrahepatic covalently closed circular DNA and serum hepatitis B surface antigen during antiviral therapy for chronic hepatitis B: lessons from experimental and clinical studies. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[200]  Shou-Dong Lee,et al.  Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[201]  M. Buti,et al.  Entecavir and Hepatitis B Immune Globulin in Patients Undergoing Liver Transplantation for Chronic Hepatitis B , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[202]  Yoshiyuki Suzuki,et al.  Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.

[203]  T. Berg,et al.  Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B , 2013, PloS one.

[204]  Huy A. Nguyen,et al.  Response to Higher Dose of Entecavir 1.0 mg Daily in Patients With Partial Response to Entecavir 0.5 mg Daily , 2013, Journal of clinical gastroenterology.

[205]  M. Colombo,et al.  755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS , 2013 .

[206]  K. Simon,et al.  Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. , 2013, Antiviral research.

[207]  R. De Francesco,et al.  IL28B polymorphisms predict interferon‐related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B , 2013, Hepatology.

[208]  M. Miquel,et al.  Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice. , 2013, Annals of hepatology.

[209]  Jie Luo,et al.  Efficacy of Entecavir Treatment for up to 5 Years in Nucleos(t)ide-Naïve Chronic Hepatitis B Patients in Real Life , 2013, International journal of medical sciences.

[210]  G. di Perri,et al.  Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[211]  F. Zoulim,et al.  Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[212]  Bernadette A. Thomas,et al.  Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 , 2012, The Lancet.

[213]  H. Janssen,et al.  Close Monitoring of Hepatitis B Surface Antigen Levels Helps Classify Flares During Peginterferon Therapy and Predicts Treatment Response , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[214]  K. Demır,et al.  Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response. , 2013, Antiviral therapy.

[215]  P. Pang,et al.  Randomized, placebo‐controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B , 2012, Hepatology.

[216]  M. Buti,et al.  factors Associated with the Lack of Achievement of Normal Alt in Chronic Hepatitis B (chb) Patients Treated with Tenofovir Df (tdf) for up to 5 Years : 411 , 2012 .

[217]  Huy Trinh,et al.  Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. , 2012, Gastroenterology.

[218]  Yoshiyuki Suzuki,et al.  Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. , 2012, Journal of hepatology.

[219]  I. Ushiro-Lumb,et al.  Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. , 2012, Gastroenterology.

[220]  X. Zhai,et al.  A predictive value of quantitative HBsAg for serum HBV DNA level among HBeAg-positive pregnant women. , 2012, Vaccine.

[221]  P. Lampertico,et al.  Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B , 2012, Gut.

[222]  Y. Liaw,et al.  Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. , 2012, Journal of hepatology.

[223]  J. Ward,et al.  Updated CDC recommendations for the management of hepatitis B virus-infected health-care providers and students. , 2012, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[224]  A. Lok,et al.  Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. , 2012, Journal of hepatology.

[225]  P. Lampertico,et al.  Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. , 2012, Journal of hepatology.

[226]  Yongjung Park,et al.  Performance evaluation of new automated hepatitis B viral markers in the clinical laboratory: two quantitative hepatitis B surface antigen assays and an HBV core-related antigen assay. , 2012, American journal of clinical pathology.

[227]  N. Terrault,et al.  The option of HBIG-free prophylaxis against recurrent HBV. , 2012, Journal of hepatology.

[228]  J. Yeon,et al.  Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus‐related decompensated cirrhosis , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[229]  P. Marcellin,et al.  Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients , 2012, Hepatology International.

[230]  Gretchen A. Stevens,et al.  Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. , 2012, Vaccine.

[231]  C. Triantos,et al.  Meta‐analysis: antiviral treatment for hepatitis D , 2012, Alimentary pharmacology & therapeutics.

[232]  A. Uitterlinden,et al.  Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. , 2012, Gastroenterology.

[233]  R. Fontana,et al.  Meta‐analysis: oral anti‐viral agents in adults with decompensated hepatitis B virus cirrhosis , 2012, Alimentary pharmacology & therapeutics.

[234]  M. Buti,et al.  Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. , 2012, Journal of hepatology.

[235]  Hong Zhang,et al.  Virologic factors associated with failure to passive–active immunoprophylaxis in infants born to HBsAg‐positive mothers , 2012, Journal of viral hepatitis.

[236]  F. Zoulim,et al.  Management of treatment failure in chronic hepatitis B. , 2012, Journal of hepatology.

[237]  V. Wong,et al.  Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. , 2011, Journal of hepatology.

[238]  M. Levrero,et al.  Control of cccDNA function in hepatitis B virus infection. , 2009, Journal of hepatology.

[239]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[240]  H. Kumada,et al.  [Chronic hepatitis B]. , 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[241]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[242]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .